Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific demonstrates robust financial growth across multiple product lines, highlighted by a remarkable 35% year-over-year increase in Watchman sales and an impressive 63% growth in the electrophysiology sector, reflecting strong market demand and share gains. The company anticipates organic sales growth of 11-13% for the fourth quarter, alongside projected GAAP EPS of $0.48-$0.52, indicating solid overall performance and revenue generation. Additionally, significant growth is expected in innovative areas, such as Nalu's projected sales exceeding $60 million in 2025 and ongoing double-digit increases in various cardiac and diagnostic sectors, affirming a positive trajectory for the firm.

Bears say

The analysis indicates a negative outlook for Boston Scientific due to several factors affecting its revenue growth. The company is expected to face a significant foreign exchange headwind of approximately $0.04 per share for the full year, alongside a slight reduction in future revenue estimates reflecting recent quarterly performance misses. Additionally, pressures within mature market segments, particularly in the cardiac rhythm management and drug-eluting stent portfolios, compounded by challenges in product integration and missed expectations in various segments, further heighten the uncertainty surrounding Boston Scientific's ability to meet internal growth projections.

Boston Scientific (BSX) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 18 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.